The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

Copyright © 2020 Elsevier Inc. All rights reserved.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 215(2020) vom: 15. Juni, Seite 108450
Auteur principal: Mastaglio, Sara (Auteur)
Autres auteurs: Ruggeri, Annalisa, Risitano, Antonio M, Angelillo, Piera, Yancopoulou, Despina, Mastellos, Dimitrios C, Huber-Lang, Markus, Piemontese, Simona, Assanelli, Andrea, Garlanda, Cecilia, Lambris, John D, Ciceri, Fabio
Format: Article en ligne
Langue:English
Publié: 2020
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Case Reports Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Antiviral Agents Complement C3 Complement Inactivating Agents Peptides, Cyclic compstatin